Cook’s Zilver PTX Safety Trial Finds No Stent Fractures
This article was originally published in The Gray Sheet
Executive Summary
Preliminary results of Cook Medical's safety trial for its Zilver PTX paclitaxel-eluting superficial femoral artery stent showed no stent fractures and a major adverse event rate equal to balloon angioplasty, the firm reports
You may also be interested in...
FDA Official Scolds Industry For Supporting Off-Label Use Of Biliary Stents
FDA is concerned that off-label use of biliary stents to open up clogged leg arteries has gotten out of control, and signaled plans last week to increase oversight of the practice
Study Shows Promise Of Stenting Leg Arteries, But Specialist Finds Weaknesses
Nitinol stents seem to work better than angioplasty in clearing clogged leg arteries, according to a study in the May 4 New England Journal of Medicine. But a leading peripheral arterial disease physician suggests that more rigorous research is needed on the matter
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.